Search

Search Constraints

You searched for: Author/Creator Delaunay, Jacques

Search Results

1. 90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Issue 3 (March 2015)

2. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies. (15th December 2016)

3. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. (7th March 2013)

4. Azacitidine for the treatment of relapsed and refractory AML in older patients. Issue 2 (February 2015)

5. Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. (2nd April 2018)

6. Azacitidine in untreated acute myeloid leukemia: A report on 149 patients. Issue 4 (6th February 2014)

7. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. Issue 10 (14th July 2015)

8. BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle. (12th September 2013)

9. Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. (27th March 2021)

10. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. Issue 7 (28th May 2015)